The role of of laccase in lignification
DM O'Malley, R Whetten, W Bao, CL Chen… - The Plant …, 1993 - Wiley Online Library
The enzymatic mechanism of monolignol polymerization in lignin biosynthesis is not known,
although it has been the subject of significant interest for more than 60 years. Peroxidase …
although it has been the subject of significant interest for more than 60 years. Peroxidase …
[HTML][HTML] A comprehensive overview of radioguided surgery using gamma detection probe technology
SP Povoski, RL Neff, CM Mojzisik, DM O'Malley… - World journal of surgical …, 2009 - Springer
The concept of radioguided surgery, which was first developed some 60 years ago, involves
the use of a radiation detection probe system for the intraoperative detection of …
the use of a radiation detection probe system for the intraoperative detection of …
Low-grade serous ovarian cancer: state of the science
In January 2019, a group of basic, translational, and clinical investigators and patient
advocates assembled in Miami, Florida, to discuss the current state of the science of low-grade …
advocates assembled in Miami, Florida, to discuss the current state of the science of low-grade …
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled …
Background Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-…
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-…
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
…, RL Coleman, AV Tinker, DM O'Malley… - The lancet …, 2017 - thelancet.com
Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian
carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 (BRCA) …
carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 (BRCA) …
Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology
…, S Lele, L Martin, UA Matulonis, DM O'Malley… - Journal of the National …, 2016 - jnccn.org
This selection from the NCCN Guidelines for Ovarian Cancer focuses on the less common
ovarian histopathologies (LCOHs), because new algorithms were added for LCOHs and …
ovarian histopathologies (LCOHs), because new algorithms were added for LCOHs and …
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
…, LT Vo, E Mann, JD Isaacson, L Maloney, DM O'Malley… - Cancer discovery, 2019 - AACR
BRCA reversion mutations are detected in cfDNA from platinum-resistant or platinum-refractory
HGOC and are associated with decreased clinical benefit from rucaparib treatment. …
HGOC and are associated with decreased clinical benefit from rucaparib treatment. …
[HTML][HTML] Pembrolizumab in patients with microsatellite instability–high advanced endometrial cancer: results from the KEYNOTE-158 study
DM O'Malley, GM Bariani, PA Cassier… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE Pembrolizumab demonstrated durable antitumor activity in patients with
previously treated, advanced microsatellite instability–high or mismatch repair–deficient (MSI-H/…
previously treated, advanced microsatellite instability–high or mismatch repair–deficient (MSI-H/…
Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United
States and is the country’s fifth most common cause of cancer mortality in women. A major …
States and is the country’s fifth most common cause of cancer mortality in women. A major …
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic …
…, BG Kim, K Fujiwara, KS Tewari, DM O'Malley… - The Lancet …, 2017 - thelancet.com
Background Platinum-based chemotherapy doublets are a standard of care for women with
ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed …
ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed …